ClinicalTrials.gg
CompletedNCT02818998VIOLETUpdated Jul 31, 2020Results posted

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Macular Edema, sponsored by Bayer. Completed at 64 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
4th of 53
463 · median 49
Started
2016
with 8 others
Phase 3
11 of 53
none open now
Registered
31st of 53
by date
Lead sponsor
9 of 53
Bayer

Among the 53 studies testing aflibercept in Macular Edema, this one is the 4th largest by enrollment, is one of 9 that started in 2016, is one of 11 in phase 3, and was the 31st registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections for approximately 1 year or more (according to the EU label for the first year of treatment)

03

Conditions studied

  • Macular Edema

Browse trials for

Keywords

  • Diabetic macular edema
  • DME
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject's history of aflibercept treatment met all of the following:

  • Treatment in the study eye was initiated with five monthly (-1 week /+2 weeks) doses of 2 mg aflibercept and improvements of visual and anatomic outcomes were observed and documented.
  • Following the above initiation phase, the intervals between treatments were between 6 weeks and 12 weeks (one exception was allowed).
  • The interval between the last 2 pre-study injections was ≥ 8 weeks, and visual and anatomic outcomes had been stable over this interval.
  • The subject received the last intravitreal (IVT) injection of aflibercept in the study eye 8 weeks (±10 days) before the first planned treatment /randomization in this study.
  • Total prior treatment duration with aflibercept (i.e. from first aflibercept treatment ever to enrollment into this study) was 1 year or longer.

To be met at initiation of pre-study aflibercept treatment:

  • Type 1 or 2 diabetes mellitus (DM)
  • Diagnosis of diabetic macular edema (DME) secondary to DM involving the center of the macula (defined as the area of the center subfield on optical coherence tomography [OCT]) in the study eye
  • Decrease in vision determined to be primarily the result of DME in the study eye
  • Best corrected visual acuity (BCVA) in the study eye of Early Treatment Diabetic Retinopathy Study (ETDRS) letter score 73 to 24

Exclusion criteria

Exclusion Criteria:

At initiation of pre-study aflibercept treatment:

  • Previous treatment with anti-angiogenic drugs in study eye (e.g., pegaptanib sodium, bevacizumab, ranibizumab, or aflibercept) within the last 12 weeks before initiation of aflibercept pre-study treatment

At initiation of pre-study aflibercept treatment, screening for this study, and baseline for this study:

  • Prior treatment of the study eye with long acting , either periocular or intraocular, in the preceding 120 days or Iluvien intravitreal implant at any time
  • Active proliferative diabetic retinopathy, current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment in the study eye
  • Cataract surgery or any other intraocular surgery within 90 days of aflibercept treatment in the study eye
  • Ocular inflammation (including trace or above) or history of uveitis in the study eye
  • Structural damage to the center of the macula in the study eye that was likely to preclude improvement in BCVA following the resolution of macular edema including atrophy of the retinal pigment epithelium, subretinal fibrosis or scar, significant macular ischemia or organized hard exudates
  • Concurrent disease in the study eye, other than DME, that could compromise visual acuity, require medical or surgical intervention during the study period, or could confound interpretation of the results (including advanced glaucoma, retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause)
  • Uncontrolled DM as defined by (Hb) A1c > 12.0% at screening and baseline for this study
  • Any ocular or periocular infection in the preceding 4 weeks in either eye
  • History of either cerebral vascular accident and/or myocardial infarction within 180 days before aflibercept treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    Aflibercept 2 mg fixed

    Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Experimental
    Aflibercept 2 mg flexible

    Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Experimental
    Aflibercept 2 mg PRN

    Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52

    Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 52

    Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

    Time frame: From baseline to week 52

  2. Number of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52

    Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity

    Time frame: From baseline to week 52

  3. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100

    Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.

    Time frame: From baseline to Week 100

  4. Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 100

    Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

    Time frame: From baseline to Week 100

  5. Number of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100

    Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity

    Time frame: From baseline to Week 100

  6. Number of Participants With Treatment-emergent Adverse Event (TEAE)

    AEs that started after the first application of aflibercept under this protocol until 30 days after the last dose of study drug administration

    Time frame: Up to Week 100

07

Results

Posted Dec 4, 2019

Participant flow

Study was conducted at multiple centers in 14 countries between 16-Nov-2016 (first participant first visit) and 24-Sep-2019 (last participant last visit).

Participant flow — Overall Study
MilestoneAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
Started155154154
Completed week 52 visit144146140
Completed137138136
Not completed181618
Withdrew: Adverse event321
Withdrew: Lost to follow-up412
Withdrew: Withdrawal by sponsor011
Withdrew: Death368
Withdrew: Withdrawal by subject766
Withdrew: Physician decision100

Outcome measures

PrimaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52

Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.

Time frame:
From baseline to Week 52
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52
Scores on a scaleAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 520.4 ± 6.70.5 ± 6.71.7 ± 6.8
Statistical analysis
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · ANCOVA · p = <0.0001 (Non-inferiority was demonstrated if the p-value (adjusted for multiplicity using the Hochberg procedure) was \< 0.025) · Least squares mean difference: 0.01 · 95% CI -1.46 to 1.47
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · ANCOVA · p = <0.0001 (Non-inferiority was demonstrated if the p-value (adjusted for multiplicity using the Hochberg procedure) was \< 0.025) · Least squares mean difference: 0.95 · 95% CI -0.52 to 2.42
SecondaryMean Change From Baseline in Central Retinal Thickness (CRT) at Week 52

Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

Time frame:
From baseline to week 52
Reported as:
Mean · Microns
Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 52
MicronsAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 52-18.8 ± 45.5-2.1 ± 56.22.2 ± 77.8
Statistical analysis
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · ANCOVA · p = 0.0105 · Least square mean difference: 14.38 · 95% CI 3.39 to 25.37
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · ANCOVA · p = 0.0023 · Least square mean difference: 21.22 · 95% CI 7.65 to 34.80
SecondaryNumber of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52

Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity

Time frame:
From baseline to week 52
Reported as:
Count of participants · Participants
Number of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52
ParticipantsAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
≥15 letter gain454
≥10 letter gain101413
≥30 letter loss100
Statistical analysis
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · Cochran-Mantel-Haenszel · Treatment difference: 0.68 · 95% CI -3.14 to 4.49
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · Cochran-Mantel-Haenszel · Treatment difference: 2.66 · 95% CI -3.40 to 8.73
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · Cochran-Mantel-Haenszel · Treatment difference: -0.66 · 95% CI -1.94 to 0.63
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · Cochran-Mantel-Haenszel · Treatment difference: -0.13 · 95% CI -3.68 to 3.41
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · Cochran-Mantel-Haenszel · Treatment difference: 1.72 · 95% CI -4.10 to 7.54
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · Cochran-Mantel-Haenszel · Treatment difference: -0.68 · 95% CI -2.00 to 0.65
SecondaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100

Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity.

Time frame:
From baseline to Week 100
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100
Scores on a scaleAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 1000.1 ± 7.2-0.1 ± 9.11.8 ± 9.0
Statistical analysis
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · ANCOVA · p = <0.0001 · Least squares mean difference: -0.30 · 95% CI -2.13 to 1.52
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · ANCOVA · p = <0.0001 · Least squares mean difference: 1.39 · 95% CI -0.40 to 3.19
SecondaryMean Change From Baseline in Central Retinal Thickness (CRT) at Week 100

Central Retinal Thickness (CRT) was measured in the study eye by spectral domain optical coherence tomography (SD-OCT).

Time frame:
From baseline to Week 100
Reported as:
Mean · Microns
Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 100
MicronsAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
Mean Change From Baseline in Central Retinal Thickness (CRT) at Week 100-15.5 ± 64.32.3 ± 81.8-13.9 ± 74.4
Statistical analysis
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · ANCOVA · p = 0.0416 · Least square mean difference: 16.14 · 95% CI 0.62 to 31.66
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · ANCOVA · p = 0.5524 · Least square mean difference: 4.12 · 95% CI -9.52 to 17.77
SecondaryNumber of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100

Best Corrected Visual Acuity (BCVA) was measured in the study eye by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score starting at 4 meters. The ETDRS chart includes 70 letters in total and the letter score ranges from 0 to 100. More letters read correctly results in a higher letter score, which represents better visual acuity

Time frame:
From baseline to Week 100
Reported as:
Count of participants · Participants
Number of Participants With Categorized Changes From Baseline in Best Corrected Visual Acuity (BCVA) at Week 100
ParticipantsAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
≥15 letter gain346
≥10 letter gain101722
≥30 letter loss122
Statistical analysis
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · Cochran-Mantel-Haenszel · Treatment difference: 0.67 · 95% CI -2.72 to 4.05
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · Cochran-Mantel-Haenszel · Treatment difference: 4.63 · 95% CI -1.73 to 10.98
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg Extended · Cochran-Mantel-Haenszel · Treatment difference: 0.66 · 95% CI -1.56 to 2.87
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · Cochran-Mantel-Haenszel · Treatment difference: 1.90 · 95% CI -1.89 to 5.69
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · Cochran-Mantel-Haenszel · Treatment difference: 7.54 · 95% CI 0.81 to 14.28
  • Aflibercept 2 mg Fixed vs Aflibercept 2 mg PRN · Cochran-Mantel-Haenszel · Treatment difference: 0.63 · 95% CI -1.61 to 2.88
SecondaryNumber of Participants With Treatment-emergent Adverse Event (TEAE)

AEs that started after the first application of aflibercept under this protocol until 30 days after the last dose of study drug administration

Time frame:
Up to Week 100
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Event (TEAE)
ParticipantsAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
Number of Participants With Treatment-emergent Adverse Event (TEAE)129128129

Adverse events

Collected over After the first application of Aflibercept under this protocol and within 30 days after the last dose of study drug administration, assessed up to Week 100.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 2 mg Fixed3/155 (1.9%)35/155 (22.6%)97/155 (62.6%)
Aflibercept 2 mg Extended6/154 (3.9%)38/154 (24.7%)85/154 (55.2%)
Aflibercept 2 mg PRN8/154 (5.2%)37/154 (24%)98/154 (63.6%)
Most frequent serious events
Showing 10 of 139
Most frequent serious events
EventAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
Myocardial infarctionCardiac disorders5/1550/1541/154
Cardiac arrestCardiac disorders0/1553/1541/154
CataractEye disorders0/1553/1541/154
Diabetic footSkin and subcutaneous tissue disorders1/1551/1543/154
Diabetes mellitusMetabolism and nutrition disorders3/1550/1541/154
Acute myocardial infarctionCardiac disorders1/1552/1542/154
Cardiac failureCardiac disorders1/1552/1542/154
Cardiac failure congestiveCardiac disorders0/1552/1540/154
PneumoniaInfections and infestations1/1552/1542/154
AngiocardiogramInvestigations0/1552/1540/154
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRN
CataractEye disorders27/15529/15424/154
Visual acuity reducedEye disorders25/15522/15422/154
Diabetes mellitusMetabolism and nutrition disorders24/15510/15415/154
Diabetic retinopathyEye disorders14/15514/15418/154
Macular oedemaEye disorders8/15511/15417/154
NasopharyngitisInfections and infestations14/15514/15417/154
Diabetic retinal oedemaEye disorders12/15513/15414/154
Cystoid macular oedemaEye disorders14/15512/15410/154
MaculopathyEye disorders3/1551/15413/154
Intraocular pressure increasedInvestigations11/1554/15411/154

Baseline characteristics

Safety analysis set (SAF): included all participants who received any study drug under the protocol.

Age, Continuous
Age, Continuous(Years)Aflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRNTotal
Mean64.3 ± 8.764.8 ± 10.165.4 ± 9.364.8 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRNTotal
Female555964178
Male1009590285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRNTotal
Hispanic or Latino1247
Not Hispanic or Latino144142142428
Unknown or Not Reported1010828
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRNTotal
American Indian or Alaska Native0000
Asian2103
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White141144147432
More than one race0000
Unknown or Not Reported119727
Best Corrected Visual Acuity (BCVA)
Best Corrected Visual Acuity (BCVA)(Scores on a scale)Aflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRNTotal
Mean72.8 ± 10.3872.5 ± 11.3571.0 ± 10.8772.1 ± 10.88
Central Retinal Thickness (CRT)
Central Retinal Thickness (CRT)(Microns)Aflibercept 2 mg FixedAflibercept 2 mg ExtendedAflibercept 2 mg PRNTotal
Mean289.8 ± 66.46285.3 ± 76.01294.5 ± 80.72289.9 ± 74.55
08

Study locations

64 sites
  • Graz, Steiermark 8036, Austria
  • Wien, 1090, Austria
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • Mississauga, Ontario L4W 1W9, Canada
  • Toronto, Ontario M3C 0G9, Canada
  • Montreal, Quebec H4P 2S4, Canada
  • Sherbrooke, Quebec J1G 2V4, Canada
  • Hradec Kralove, 500 05, Czechia
  • Praha 10, 100 34, Czechia
  • Creteil Cedex, 94010, France
  • Darmstadt, Hessen 64297, Germany
  • Frankfurt, Hessen 60596, Germany
  • Marburg, Hessen 35043, Germany
  • Göttingen, Niedersachsen 37075, Germany
  • Bonn, Nordrhein-Westfalen 53105, Germany
  • Köln, Nordrhein-Westfalen 50924, Germany
  • Dresden, Sachsen 01307, Germany
  • Budapest, 1085, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Debrecen, 4032, Hungary
  • Pecs, 7621, Hungary
  • Roma, Lazio 00133, Italy
  • Genova, Liguria 16132, Italy
  • Milano, Lombardia 20122, Italy
  • Milano, Lombardia 20132, Italy
  • Torino, Piemonte 10122, Italy
  • Cagliari, Sardegna 09124, Italy
  • Sassari, Sardegna 07100, Italy
  • Firenze, Toscana 50134, Italy
  • Padova, Veneto 35128, Italy
  • Kaunas, LT-50009, Lithuania
  • Vilnius, LT-08661, Lithuania
  • Bydgoszcz, 85-631, Poland
  • Gdansk, 80-809, Poland
  • Katowice, 40-594, Poland
  • Krakow, 31-501, Poland
  • Lodz, 91-134, Poland
  • Lublin, 20-081, Poland
  • Poznan, 61-285, Poland
  • Warszawa, 01-013, Poland
  • Warszawa, 04-141, Poland
  • Vila Franca de Xira, Lisboa 2600-178, Portugal
  • Coimbra, 3000-548, Portugal
  • Leiria, 2410-197, Portugal
  • Lisboa, 1649-035, Portugal
  • Porto, 4200-319, Portugal
  • Bratislava, 826 06, Slovakia
  • Bratislava, 851 07, Slovakia
  • Nitra, 949 01, Slovakia
  • Zilina, 01207, Slovakia
  • Zvolen, 960 01, Slovakia
  • L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Sant Cugat del Vallés, Barcelona 08195, Spain
  • Albacete, 02006, Spain
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Valencia, 46014, Spain
  • Bern, Switzerland
  • Genève, 1204, Switzerland
  • Southampton, Hampshire SO16 6YD, United Kingdom
  • Sunderland, Tyne And Wear SR2 9HP, United Kingdom
  • Leeds, West Yorkshire LS9 7TF, United Kingdom
  • London, EC1V 2PD, United Kingdom
09

References and documents

Publications

  • Garweg JG, Stefanickova J, Hoyng C, Niesen T, Schmelter T, Leal S, Sivaprasad S; VIOLET Investigators. Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial. Adv Ther. 2022 Jun;39(6):2701-2716. doi: 10.1007/s12325-022-02119-z. Epub 2022 Apr 12. PubMed 35412227 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Nov 2018, 23 months.

Results were first posted in Dec 2019, 1 year after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 23 months is close to that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2016
First posted
Jun 30, 2016
StartActual
Nov 16, 2016
Primary completionActual
Nov 13, 2018
CompletionActual
Sep 24, 2019
Results first posted
Dec 4, 2019
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02818998
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 30, 2016
Start date
Nov 16, 2016
Primary completion
Nov 13, 2018
Completion
Sep 24, 2019
Results posted
Dec 4, 2019
Last update
Jul 31, 2020

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion